Skip to main content
LQDA
NASDAQ Life Sciences

Liquidia Reports Strong Q1 Profitability and YUTREPIA Sales Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$43.5
Mkt Cap
$3.727B
52W Low
$11.85
52W High
$46.67
52W Position info
267% above low
Off High info
6.8% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

LQDA has more than doubled off its 52-week low of $11.85.

Summary

Liquidia reported its third consecutive profitable quarter with strong Q1 2026 financial results, driven by robust YUTREPIA sales and a significant increase in cash reserves.


Key Events · Earnings and Guidance · LQDA

  • Record Profitability

    Reported net income of $52.9 million and adjusted EBITDA of $71.2 million for Q1 2026, marking the third consecutive profitable quarter.

  • Strong YUTREPIA Sales

    Achieved $129.9 million in net product sales for YUTREPIA, driven by over 4,500 unique patient prescriptions and approximately 3,750 patients treated since launch.

  • Enhanced Financial Position

    Increased cash and cash equivalents by $32.1 million to $222.8 million as of March 31, 2026.

  • Clinical Pipeline Advancement

    Progressed Phase 4 studies for YUTREPIA and initiated the pivotal Phase 3 Re-Spire study for L606.


Analysis · LQDA · Life Sciences

Liquidia Corporation announced robust first-quarter results, demonstrating accelerating profitability with a significant increase in net income and adjusted EBITDA. The continued strong performance of YUTREPIA, evidenced by substantial sales and patient uptake, is driving this financial strength. The company's cash position also improved considerably, providing a solid foundation for ongoing clinical development.

How filings like this one have moved

In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LQDA was trading at $43.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $11.85 to $46.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LQDA - Latest Insights

LQDA
Sep 30, 2026, 1:20 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $53.22
Real-time Price: $29.76 info
Change: -$23.46 (-44%) info
Market Cap: $2.709B info
LQDA
Sep 30, 2026, 11:42 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $53.22
Real-time Price: $29.76 info
Change: -$23.46 (-44%) info
Market Cap: $2.709B info
LQDA
Sep 03, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $70.20
Real-time Price: $29.76 info
Change: -$40.44 (-58%) info
Market Cap: $2.709B info
LQDA
Sep 03, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $72.17
Real-time Price: $29.76 info
Change: -$42.41 (-59%) info
Market Cap: $2.709B info
LQDA
Aug 12, 2026, 6:45 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $87.00
Real-time Price: $29.76 info
Change: -$57.24 (-66%) info
Market Cap: $2.709B info